Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00325065 |
The goal of this protocol, broadly stated, is to use targeted manipulations with intranasally administered oxytocin (OT) and arginine vasopressin (AVP) in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate, respectively, the effective processing of aversive signals. Moreover, we wish to examine whether increased vasopressin levels will increase, and increased oxytocin levels decrease, the neural response in the amygdala and other limbic structures to aversive stimuli. In addition, we wish to assess whether OT and AVP administration will lead to the facilitation of conspecific recognition as appears to be the case for other mammalian species....
Condition |
---|
Mood Disorders |
Study Type: | Observational |
Official Title: | Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders |
Estimated Enrollment: | 216 |
Study Start Date: | May 2006 |
The goal of this protocol, broadly stated, is to use targeted manipulations with intranasally administered oxytocin (OT) and arginine vasopressin (AVP) in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate, respectively, the effective processing of aversive signals. Moreover, we wish to examine whether increased vasopressin levels will increase, and increased oxytocin levels decrease, the neural response in the amygdala and other limbic structures to aversive stimuli. In addition, we wish to assess whether OT and AVP administration will lead to the facilitation of conspecific recognition as appears to be the case for other mammalian species.
Ages Eligible for Study: | 20 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
INCLUSION CRITERIA:
EXCLUSION CRITERIA:
Because factors such as psychiatric disease or CNS disease can influence functional brain activity, these factors are exclusionary.
ADDITIONAL EXCLUSION CRITERIA FOR FMRI STUDIES:
Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
Contact: TTY | 1-866-411-1010 |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 |
Study ID Numbers: | 060155, 06-M-0155 |
Study First Received: | May 11, 2006 |
Last Updated: | October 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00325065 |
Health Authority: | United States: Federal Government |
Amygdala Emotion Memory Threat Peptides |
Neuropeptides Oxytocin Vasopressin Mood Disorder |
Arginine Vasopressin Mental Disorders Vasopressins Mood Disorders Oxytocin |
Disease Coagulants Oxytocics Hematologic Agents Physiological Effects of Drugs Reproductive Control Agents Cardiovascular Agents |
Hemostatics Pharmacologic Actions Pathologic Processes Natriuretic Agents Therapeutic Uses Vasoconstrictor Agents Antidiuretic Agents |